Conference abstractPublished 17 Oct 2016
Pharmacogenetics of toxicity to fluoropyrimidines
Gregorio Marañón Hospital, Spain
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Adverse reactions (ADRs) to chemotherapy agents, which can lead to treatment discontinuations and to the loss of treatment lines, are one of the major issues in the treatment of colorectal cancer. Individual genetic variants affect susceptibility to these adverse reactions. Several polymorphisms have been identified although they still need validation due to controversial results. Furthermore, new genetic variants need to be identified to increase the prediction power of existing tests. The aim of our work is to validate previously identified polymorphisms and to identify new variants. Three different approaches were followed: an association study of previously identified SNPs with adverse reactions to capecitabine-based treatments in a cohort of colorectal cancer patients, an association study of tag-SNPs with adverse reactions to capecitabine-based treatments in the same cohort, and a whole exome study in eight colorectal cancer patients suffering from high toxicity to capecitabine-based treatments. Results validate several SNPs associated with ADR to capecitabine in CRC. A test can identify patients at high risk of severe overall toxicity more precisely than regular tests. Tag-SNPs allow identifying new SNPs related to ADR in fluoropyrimidine-treated patients. Finally, exome sequencing allows us to obtain a complete profile of genetic variants in exons, splice sites and 5’ and 3’ untranslated regions in all genes participating in fluoropyrimidine pathway. In summary, this global approach is an excellent way to increase the knowledge of fluoropyrimidine-related adverse reaction pharmacogenetics and to increase the predictive power of pharmacogenetic tests in this field.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Luis A Lopez-Fernandez”